Cytochrome P450 2C19 loss-of- function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916 22. 25. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363 75. 26. Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19*2 poly- morphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011;11:199 206. 27. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G3A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925 34. 28. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic poly- morphisms and the response to prasugrel: relationship to pharmaco- kinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119:2553 60. 29. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopi- dogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009;30:1744 52. 30. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844 51. 31. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306:2704 14. 32. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1243. 33. Mehta SR, Bassand JP, Chrolavicius S, et al. 